Literature DB >> 9832943

Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW373U86 and SNC 80: 2. Place-preference and brain microdialysis studies in rats.

R Longoni1, C Cadoni, A Mulas, G Di Chiara, L Spina.   

Abstract

The motivational properties of the non-peptide delta-opioid receptor agonists BW373U86 and SNC 80 were investigated using the place-conditioning paradigm. BW373U86 (0.5-1.0 mg/kg s.c.) and SNC 80 (1.25-5.0 mg/kg s.c.) elicited significant preference for the drug-paired compartment, in a dose-related fashion. Naltrindole (5.0 mg/kg s.c.) pretreatment, while failing to modify preference when given alone, completely prevented place-preference induced by BW373U86 (1.0 mg/kg s.c.) and SNC 80 (1.25 mg/kg s.c.). The dopamine D1 receptor antagonist SCH23390, given at doses that do not affect place-preference (0.012 mg/kg s.c.), completely prevented the place-preference induced by BW373U86 and SNC 80. At the doses effective in eliciting place-preference, BW373U86 and SNC 80 failed to modify extracellular dopamine in the medial nucleus accumbens, while in the dorso-lateral caudate-putamen BW373U86 (1.0 and 2.5 mg/kg s.c.) reduced extracellular dopamine, and this effect was prevented by naltrindole (5.0 mg/kg s.c.). SNC 80, only at the dose of 5 mg/kg s.c., significantly reduced extracellular DA in the dorso-lateral caudate-putamen. The results indicate that stimulation of delta-opioid receptors has incentive properties that might be related to an indirect amplification of post-synaptic dopamine transmission.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832943

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  14 in total

1.  Effects of yohimbine on the antinociceptive and place conditioning effects of opioid agonists in rodents.

Authors:  L Morales; C Perez-Garcia; L F Alguacil
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Sex differences in the effects of adolescent social deprivation on alcohol consumption in μ-opioid receptor knockout mice.

Authors:  Yuki Moriya; Yoshiyuki Kasahara; F Scott Hall; Yasufumi Sakakibara; George R Uhl; Hiroaki Tomita; Ichiro Sora
Journal:  Psychopharmacology (Berl)       Date:  2014-11-04       Impact factor: 4.530

3.  β-endorphin via the delta opioid receptor is a major factor in the incubation of cocaine craving.

Authors:  Yahav Dikshtein; Royi Barnea; Noam Kronfeld; Elad Lax; Ilana Roth-Deri; Alexander Friedman; Iris Gispan; Einat Elharrar; Sarit Levy; Moshe Ben-Tzion; Gal Yadid
Journal:  Neuropsychopharmacology       Date:  2013-06-26       Impact factor: 7.853

4.  Automated touch screen device for recording complex rodent behaviors.

Authors:  O S Mabrouk; I J Dripps; S Ramani; C Chang; J L Han; K C Rice; E M Jutkiewicz
Journal:  J Neurosci Methods       Date:  2014-06-19       Impact factor: 2.390

Review 5.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

6.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

7.  The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats.

Authors:  Gail Pereira Do Carmo; John E Folk; Kenner C Rice; Elena Chartoff; William A Carlezon; S Stevens Negus
Journal:  Eur J Pharmacol       Date:  2008-12-24       Impact factor: 4.432

8.  The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2008-06-18       Impact factor: 5.250

Review 9.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

10.  Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Kristin N Schultz-Kuszak; Omar S Mabrouk; Robert T Kennedy; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.